Carcinoma Transitional Cell/mortality/surgery Cystectomy Disease-Free Survival Humans Nephroureterectomy Prognosis *Sex Factors Urinary Bladder Neoplasms/*mortality/*surgery Urologic Neoplasms/*mortality/*surgery carcinoma meta-analysis review [publication type] transitional cell urinary bladder neoplasms

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma

Adjuvants Immunologic/therapeutic use BCG Vaccine/therapeutic use Evidence-Based Medicine Humans Neoplasm Invasiveness Neoplasm Recurrence Local/*therapy Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin unresponsive Bladder preservation therapy Bladder sparing Non–muscle-invasive bladder cancer

Anti-Bacterial Agents/therapeutic use Antibiotic Prophylaxis Humans Meta-Analysis as Topic Postoperative Complications/drug therapy Systematic Reviews as Topic *Urinary Bladder Neoplasms/drug therapy/surgery *Urinary Tract Infections/drug therapy/prevention & control Antibiotic resistance Antibiotics Antimicrobial stewardship Bacteriuria Endourological surgery Guideline Recommendation Transitional cell carcinoma Urothelium cell carcinoma

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant/methods Cisplatin/therapeutic use Clinical Decision-Making/methods *Cystectomy Disease-Free Survival Female Humans Male Neoadjuvant Therapy/methods Neoplasm Recurrence Local/*epidemiology/pathology/prevention & control Neoplasm Staging Patient Selection *Sex Factors Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*therapy Adjuvant chemotherapy Bladder cancer Gender Meta-analysis Neoadjuvant chemotherapy

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage Antimetabolites Antineoplastic/*administration & dosage Deoxycytidine/administration & dosage/*analogs & derivatives Humans Mitomycin/*administration & dosage Neoplasm Invasiveness Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Gemcitabine Bladder cancer Meta-analysis Mitomycin Systematic evaluation

Cystectomy/adverse effects Humans Postoperative Complications/diagnosis/epidemiology/etiology Risk Factors *Robotic Surgical Procedures/adverse effects *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures *Urology Complications European Association of Urology guidelines Outcome reporting Robot-assisted radical cystectomy Standardised tool

5-alpha Reductase Inhibitors/therapeutic use Androgen Antagonists/therapeutic use Androgens/therapeutic use *Carcinoma in Situ Humans Male *Prostatic Neoplasms/pathology *Urinary Bladder Neoplasms/pathology *Androgen suppression therapy *Androgens *Bladder cancer *Incidence *Recurrence *Systematic review

Carcinoma Transitional Cell/epidemiology/*pathology Disease Progression Humans Neoplasm Invasiveness Neoplasm Recurrence Local/epidemiology Neoplasm Staging Prognosis Urinary Bladder Neoplasms/epidemiology/*pathology Bladder cancer Progression Staging Substage T1 Urothelial carcinoma pT1

Cystectomy/adverse effects/*methods Humans Laser Therapy/adverse effects/*methods Neoplasm Invasiveness Treatment Outcome Urethra Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Laser surgery Systematic review and meta-analysis Transurethral resection

Cystectomy/*methods Humans Neoplasm Invasiveness Urethra Urinary Bladder Neoplasms/pathology/*surgery Bladder tumor En bloc resection Meta-analysis Transurethral resection

5 alpha reductase inhibitors androgen deprivation therapy androgen receptor bladder cancer

Arylamine N-Acetyltransferase/*genetics Asian People/genetics Humans *Polymorphism Single Nucleotide Smoking/epidemiology Urinary Bladder Neoplasms/epidemiology/ethnology/*genetics White People/genetics Bladder cancer Meta-analysis N-acetyltransferase 2 Polymorphism competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

*Cystectomy/methods Humans Postoperative Complications/*epidemiology Prognosis Survival Rate Urinary Bladder Neoplasms/*mortality/*surgery Bladder cancer clinical markers morbidity mortality radical cystectomy survival

Biomarkers/urine DNA Mutational Analysis DNA Neoplasm/*urine Disease Progression Humans Mutation Neoplasm Recurrence Local/*diagnosis/genetics/*urine Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/genetics/*urine #BladderCancer #blcsm biomarkers molecular diagnostics urinary bladder neoplasms urine analysis Amsterdam UMC location VUmc. J. Bosschieter R.D.M. Steenbergen and J.A. Nieuwenhuijzen are inventors on patent(s) related to the work.

Aged Carcinoma Transitional Cell/*surgery *Cystectomy/methods Female Humans *Lymph Node Excision Male Middle Aged Postoperative Complications Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/*surgery

Anastomosis Surgical/adverse effects/instrumentation/methods Constriction Pathologic/etiology Cystectomy/*instrumentation/methods Humans Ileum/surgery Incidence Postoperative Complications/etiology Stents/*adverse effects Ureter/surgery Ureteral Obstruction/*etiology Urinary Bladder Neoplasms/surgery Urinary Catheters/adverse effects Urinary Diversion/adverse effects/*instrumentation/methods Cystectomy Internal double-J stent Orthotopic neobladder Ureteroileal anastomosis stricture Urinary diversion

肌层浸润性膀胱癌 保留膀胱 根治性切除 Meta分析 疗效评价

Humans Odds Ratio Prospective Studies *Urinary Bladder Neoplasms *Vitamin E bladder cancer meta-analysis vitamin E

膀胱癌 lncRNA UCA1 Meta分析